Laryngeal Mask Supreme™ Versus the I-gel™
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Apr 3, 2008
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
The LMA Supreme™ and the I-gel™ are both new developed supraglottic airway devices to provide patent airways during general anesthesia. So far, prospective randomized controlled trials comparing their performance are not yet published. Both devices can be used in difficult airway situations, pre-hospital and in the hospital. In this prospective, randomized, controlled cross-over trial, we are going to evaluate the performance of both devices in a simulated difficult airway scenario using an extrication collar to limit both mouth opening and neck movement. In a maximum total of 60 patients u...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ASA 1-3 patients undergoing elective operation
- Exclusion Criteria:
- • Not speaking german or refusing to participate
- • BMI \>35, \<50kg
- • Planned operation time \>4h
- • High risk of aspiration
- • Cervical spine disease, known difficult airway, mouth opening \<20mm
- • Upper respiratory tract symptoms in the previous 10 days
- • Preoperative sore throat
- • Poor dentition with high risk of damage
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Berne, , Switzerland
Patients applied
Trial Officials
Robert Greif, M.D.
Study Director
Department of Anesthesia, University Hospital Berne, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials